Dementia

BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference

Tuesday, May 11, 2021 - 12:00pm

BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders and dementia.

Key Points: 
  • BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders and dementia.
  • The Company recently submitted its New Drug Application to the FDA for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.
  • The safety and efficacy of BXCL501 has not been established.\nBioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
  • BioXcel\xe2\x80\x99s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease

Monday, May 10, 2021 - 1:30pm

b"AUSTIN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer\xe2\x80\x99s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer\xe2\x80\x99s disease.

Key Points: 
  • b"AUSTIN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer\xe2\x80\x99s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer\xe2\x80\x99s disease.
  • The CMS design includes measures of safety and a single primary endpoint of cognition, measured on ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale).
  • Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimer\xe2\x80\x99s disease with a simple blood test.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer\xe2\x80\x99s disease.

Global Dementia Epidemiology and Patient Flow Analysis & Forecasts 2020-2035 - ResearchAndMarkets.com

Monday, May 10, 2021 - 9:44am

b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dementia patients, history of the disease at the population level (Dementia prevalence, Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Dementia patients segments through age groups, gender, and disease sub-types\n'

2021 Global Lewy Body Dementia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Friday, May 7, 2021 - 2:44pm

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Lewy Body Dementia patients, history of the disease at the population level (Lewy Body Dementia prevalence, Lewy Body Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nLewy Body Dementia patient flow: Lewy Body Dementia prevalence, diagnosed, and drug-treated patients\nDemographics: Lewy Body Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Lewy Body Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Lewy Body Dementia patients segments through age groups, gender, and disease sub-types\nEvaluate Lewy Body Dementia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005374/en/\n'

Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy

Thursday, May 6, 2021 - 11:45am

The two previously issued patents cover AD and alpha-synucleopathies, such as PD; the new patent covers tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy.

Key Points: 
  • The two previously issued patents cover AD and alpha-synucleopathies, such as PD; the new patent covers tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy.
  • This latest patent was issued because ANVS401 lowers the levels of tau and phospho-tau.\nFrom the acute patent family, which provides intellectual property protection through 2036, Annovis Bio has been issued two patents: one covering Europe and one covering Japan.
  • "Our unique approach to treating neurodegeneration targets the same toxic cascade leading to nerve cell death in chronic as well as acute brain injuries.
  • "\nANVS401 and ANVS405 can work in chronic and acute indications because nerve cells die by the same mechanism in these diseases.

Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

Thursday, May 6, 2021 - 11:30am

KarXT is currently being evaluated as a potential treatment for psychiatric disorders, including schizophrenia and dementia-related psychosis.\nKarXT for the treatment of psychosis in adults with schizophrenia.

Key Points: 
  • KarXT is currently being evaluated as a potential treatment for psychiatric disorders, including schizophrenia and dementia-related psychosis.\nKarXT for the treatment of psychosis in adults with schizophrenia.
  • 10,933,020 and 10,925,832 related to compositions and methods for treating disorders ameliorated by muscarinic receptor activation.\nCOVID-19 update.
  • Our actual results could differ materially from the results described in or implied by such forward looking statements.
  • Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.\n"

Memore Launches Functional Whole Food Blends for Sustainable Cognitive Health

Tuesday, May 4, 2021 - 1:00pm

b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.

Key Points: 
  • b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.
  • Founded by husband-wife duo Brad and Erika Lepczyk, Memore carves out an important place in the consumer space for sustainable cognitive health solutions.\nEach Memore pouch contains 30 servings of brain-boosting nutrients thanks to high-quality ingredients derived from 11 whole foods and three plant-based protein sources.
  • Memore products are loaded with whole food ingredients, including brain-boosters like blueberry, spinach, sweet potato and beet.
  • To learn more, please visit www.yourmemore.com and follow @yourmemore on Instagram and Facebook .\nFounded in 2021, Memore is a company dedicated to sustainable cognitive health that offers functional blends that conveniently fill gaps in your diet with whole food nutrition shown to improve cognition, slow cognitive decline and reduce your risks of Alzheimer\'s dementia.

Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021

Tuesday, May 4, 2021 - 1:00pm

b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.

Key Points: 
  • b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.
  • The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
  • Yumanity\xe2\x80\x99s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases.
  • Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.

GammaBoost®, the app defying Alzheimer's

Tuesday, May 4, 2021 - 12:07pm

b'HENDERSON, Nev., May 4, 2021 /PRNewswire/ -- For those who are suffering, GammaBoost may curb memory loss and combat some of the terrible effects of Alzheimer\'s.

Key Points: 
  • b'HENDERSON, Nev., May 4, 2021 /PRNewswire/ -- For those who are suffering, GammaBoost may curb memory loss and combat some of the terrible effects of Alzheimer\'s.
  • The app is also intended for those at risk or over 50, who are encouraged to use GammaBoost daily as a preventive measure.\nGDI LLC developed the GammaBoost app in response to numerous published scientific studies, such as those by the National Institute on Aging[1] and the Massachusetts Institute of Technology[2].
  • After one hour, it turns off automatically and plays a notification sound.
  • For further information, visit http://www.24-7pressrelease.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/gammaboost-the-app-defying-alzhe...\n'

Tombot, creator of the first affordable, FDA-regulated medical robotic animal, is now accepting investors

Monday, May 3, 2021 - 10:30pm

Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.

Key Points: 
  • Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.
  • Tombot\'s research showed seniors strongly prefer robotic animals with realistic appearance and behaviors.\nTombot\'s Co-founder and CEO, Tom Stevens, founded the company based upon his mother Nancy Stevens\' personal battle with Alzheimer\'s dementia.
  • We\'re focusing on the needs of one patient at a time and making sure we can provide them with the necessary medical benefits.
  • You can learn more about Tombot and invest through their offering page here .\n'